Advanced Biomed Inc. focuses on the early screening, detection, diagnosis, staging, and treatment of cancer. Listed on the Nasdaq Capital Market under the ticker ADVB, the company develops microfluidic biochip technologies aimed at identifying and analyzing circulating tumor cells (CTCs) that shed from tumors and circulate in the bloodstream. From what I see, investors track the company for its role in precision oncology and the liquid-biopsy market, where interest is growing in less invasive, blood-based testing methods.
Advanced Biomed was founded in Taiwan in September 2014, and its main operations, design, and development continue to be based there. The U.S.-listed entity is an investment holding company incorporated in Nevada, operating through subsidiaries such as Advanced Biomed Inc. (Taiwan) and Advanced Biomed HK Limited, with headquarters in Tainan, Taiwan. I also checked this using Tickeron’s AI Screener to compare its profile with other names in the sector.
The core emphasis is on combining semiconductor techniques with biotechnology to create a proprietary microfluidic platform. This platform detects circulating tumor cells and related markers in blood samples, captures single CTCs, and supports single-cell sorting and analysis. In practice, the technology applies across the cancer care spectrum, from early screening and diagnosis to treatment monitoring.
The product lineup features several instruments and consumables. Key devices include A+Pre, an automated system for pre-concentrating blood samples; AC-1000, designed to enrich rare cells; A+SCDrop, for capturing individual circulating tumor cells; and A+CellScan, an analyzer with an immunostaining chip. These pair with biochips such as the A+Pre Chip, AC-1000 CTC Enrichment Chip, and A+CellScan Chip.
The company has also developed immunostaining kits including A+CTCE, A+CTCM, A+EMT, and A+CM, which use fluorescent-labeled antibodies to identify various tumor cell types. Additionally, A+LCGuard targets early lung cancer screening to differentiate benign from malignant pulmonary nodules. This setup follows a razor-and-blade model, where instruments and biochips drive recurring demand for assay kits and services.
As an early-stage firm, Advanced Biomed generates modest revenue so far and maintains a limited employee base. Its financials reflect ongoing development, with research and development plus commercialization costs outpacing current revenue while it seeks regulatory approvals and market entry. Primary operations are in Taiwan and Greater China through medical clinics, alongside plans for centers in North America and Europe.
One thing that stands out is the company's positioning in the expanding liquid-biopsy and precision-oncology field. Liquid biopsy involves minimally invasive tests that analyze tumor material from bodily fluids like blood instead of traditional tissue samples. The CTC-focused technology fits within this market, which is growing as healthcare systems prioritize earlier and less invasive detection.
Its competitive edge comes from an integrated platform covering sample preparation, enrichment, capture, and analysis. The emphasis on different CTC subtypes—epithelial, mesenchymal, and epithelial-to-mesenchymal transition—addresses nuances in cancer biology that can influence treatment choices. Products like A+LCGuard also meet a specific need in assessing lung nodules detected through imaging.
Strategically, the company is advancing regulatory clearances and geographic expansion, which could support longer-term growth. Commercialization efforts in China and planned moves into North American and European markets aim to scale the technology beyond Taiwan. For those interested in oncology diagnostics and early-stage biotechnology, ADVB provides exposure to a specialized area of cancer detection.
Investing in Advanced Biomed involves substantial risks common to early-stage biotechnology companies. The financial profile shows limited revenue and ongoing operating losses, while the relatively small market capitalization can lead to higher stock-price volatility and lower liquidity. There is no assurance that its products will achieve broad commercial success.
Regulatory and clinical risks are significant as well. Pipeline products need approvals across multiple regions, and clearance in one market does not ensure it elsewhere. Delays, extra data requirements, or unfavorable decisions could materially impact the business. The company also operates in a competitive diagnostics industry with larger, better-funded players in overlapping areas of oncology testing and liquid biopsy.
Operations are concentrated in Taiwan and Greater China, which introduces geographic, macroeconomic, and geopolitical risks along with potential shifts in healthcare reimbursement and policy. The narrow revenue base and reliance on successful commercialization of a focused product set are key factors for anyone evaluating the stock.
In my view, Tickeron’s AI Screener offers a practical way to screen stocks and ETFs using technical indicators, fundamentals, volatility, trends, AI signals, industries, patterns, and custom filters. It helps surface ideas that match specific strategies, whether growth, value, momentum, or income focused. For anyone looking at names like Advanced Biomed or the wider biotechnology space, it provides a structured approach to compare opportunities efficiently.
Advanced Biomed (ADVB) is an early-stage biotechnology company with an integrated microfluidic platform for cancer detection and treatment based on circulating tumor cell analysis. Its overview shows a development-stage business with a targeted product range of devices, biochips, and immunostaining kits, positioned in the emerging liquid-biopsy area. While growth ambitions in precision oncology and expansion are notable, the limited revenue, ongoing losses, and early regulatory status point to a high-risk profile that warrants careful evaluation.
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
On November 12, 2026, the Stochastic Oscillator for ADVB moved out of oversold territory and this could be a bullish sign for the stock. Traders may want to buy the stock or buy call options. Tickeron's A.I.dvisor looked at 22 instances where the indicator left the oversold zone. In 20 of the 22 cases the stock moved higher in the following days. This puts the odds of a move higher at over 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ADVB's RSI Oscillator exited the oversold zone, 11 of 13 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 85%.
The Momentum Indicator moved above the 0 level on November 12, 2026. You may want to consider a long position or call options on ADVB as a result. In 35 of 37 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 90%.
The Moving Average Convergence Divergence (MACD) for ADVB just turned positive on November 09, 2026. Looking at past instances where ADVB's MACD turned positive, the stock continued to rise in 15 of 17 cases over the following month. The odds of a continued upward trend are 88%.
Following a +56.87% 3-day Advance, the price is estimated to grow further. Considering data from situations where ADVB advanced for three days, in 62 of 73 cases, the price rose further within the following month. The odds of a continued upward trend are 85%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ADVB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.
ADVB broke above its upper Bollinger Band on November 12, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Aroon Indicator for ADVB entered a downward trend on November 13, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Valuation Rating of 56 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.207) is normal, around the industry mean (67.298). P/E Ratio (1.688) is within average values for comparable stocks, (4.239). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (3.473). Dividend Yield (0.000) settles around the average of (0.002) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (9.775).
The Tickeron PE Growth Rating for this company is 59 (best 1 - 100 worst), pointing to average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. ADVB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADVB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 86, placing this stock worse than average.
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Industry MedicalSpecialties